Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

Exclusion Criteria

• •Advanced stage disease (AA stage III-IV)
• •Extranasal type NKTCL
• •History of autoimmune disease
• •History of other(s) infiltrating cancer(s) in the previous 3 years that were not treated with curative intent or who are still receiving anticancer therapy (including hormone therapy for breast or prostate cancer).
• •History of (non-infectious) pneumonitis that required steroids; evidence of interstitial lung disease or active, non-infectious pneumonitis
• •Active infection requiring systemic therapy
• •Significant cardiovascular disease, myocardial infarction in the previous 3 months, unstable arrhythmias, or unstable angina.
• •Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
• •HBsAg, HCV or HIV positivity. Positive serology is admitted for HBV and HCV but DNA/RNA test must be negative
• •Administration of a live attenuated vaccine within 4 weeks before cyle 1 day 1. Patients must not receive live, attenuate vaccines, including influenza vaccines at any time during study.
• •Treatment with systemic immunosuppressive medications, including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide and anti tumor necrosis factor (anti-TNF) agents within 2 weeks prior to cycle 1 day 1; inhaled corticosteroids are allowed.
• •Evidence of suspect of CNS disease
• •Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound Pembrolizumab itself or to the excipients in its formulation).
• •Has had an allogenic tissue/solid organ transplant
• •Known history of active TB (Bacillus Tuberculosis)